BIOMARKERS TO PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITOR THERAPY IN CANCER

BIOMARKERS TO PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITOR THERAPY IN CANCER
Author(s):
Kriti Jain, Shyam Aggarwal, Surajit Ganguly, Nirmal Kumar Ganguly, Amit Awasthi, Deepa Mehra
Keywords:
Immune checkpoint inhibitors, PD1/PD-L1, CTLA4, biomarkers, immunotherapy, solid tumors, predictive biomarkers
Abstract
Traditional treatment modalities for advanced cancer act directly on tumors to inhibit growth or destroy them. Along with surgery, these modalities are predominantly palliative, though associated with toxicity and modest improvements in survival of patients with advanced solid tumors. To address these issues, novel immunotherapies targeting programmed death-1 (PD-1/PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA4) have been developed and approved by the FDA. These therapies have been proven to provide substantial benefit and success in advanced solid tumors of different types. However, these expensive checkpoint inhibitor therapies extend clinical benefits to only a small subset of patients. Hence, it is crucial to comprehend the determinants and the role of biomarkers that drive response, resistance, and adverse effects. In this review, we have elaborated on the role of various biomarkers both pre-treatment and post-treatment which assist in predicting response to immune checkpoint inhibitors in cancer treatment.
Article Details
Unique Paper ID: 156858 Publication Volume & Issue: Volume 9, Issue 5 Page(s): 205 - 221
Article Preview & Download

Share This Article

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024

Last Date: 15th March 2024

IJIRT.org enables door in research by providing high quality research articles in open access market.

Send us any query related to your research on editor@ijirt.org